Cargando…
A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma
BACKGROUND: The objective of this randomized placebo-controlled study was to investigate the efficacy and safety of clarithromycin in combination with bortezomib–cyclophosphamide–dexamethasone (VCD) in patients with newly diagnosed multiple myeloma eligible for high-dose therapy. METHODS: Patients w...
Autores principales: | Gregersen, Henrik, Do, Trung, Kristensen, Ida Bruun, Frølund, Ulf Christian, Andersen, Niels Frost, Nielsen, Lene Kongsgaard, Andersen, Christen Lykkegaard, Klausen, Tobias Wirenfeldt, Vangsted, Annette Juul, Abildgaard, Niels |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090810/ https://www.ncbi.nlm.nih.gov/pubmed/30123673 http://dx.doi.org/10.1186/s40164-018-0110-0 |
Ejemplares similares
-
The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population‐based study
por: Gregersen, Henrik, et al.
Publicado: (2017) -
Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial
por: Johnsen, Hans E, et al.
Publicado: (2009) -
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
por: Gregersen, Henrik, et al.
Publicado: (2021) -
The Danish National Multiple Myeloma Registry
por: Gimsing, Peter, et al.
Publicado: (2016) -
Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)